CLSD's Business Model
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.clearsidebio.com |
| CEO (Chief Executive Officer) | George M. Lasezkay Pharm.D., Pharma.D. |
| Number of Employees | |
| IPO date | June 2, 2016 |
CLSD Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 900 North Point Parkway |
| City | Alpharetta |
| State | GA |
| Phone | 678 270 3631 |
| Zip Code | 30005 |
| Other Identifiers | |
| CIK | 0001539029 |
| ISIN | US1850631045 |
| CUSIP | 185063104 |
| Open | 0.83 |
| Previous Close | 0.8123 |
| Volume | 114.4 Thou. |
| Average Volume | 237.6 Thou. |
| Day’s Range | 0.81 – 0.8395 |
| 52 Week Range | 0.7-1.65 |
| MA (50) | 0.8247 |
| MA (200) | 0.97161 |
| Market Cap | 63.33 Mil. |
| Shares Out. | 77.71 Mil. |
| Earnings Date | Aug 11, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
